Groundbreaking Discovery of a Treatable Mesothelioma Variant Emphasizes Early Detection and Genetic Testing

Researchers at the University of Hawaiʻi Cancer Center have identified a new, less aggressive form of mesothelioma, offering new hope for patients through improved diagnosis and targeted treatment. Led by scientists Michele Carbone and Haining Yang, their findings, published in the Journal of Thoracic Oncology, reveal a genetic variant called low-grade BAP1-associated mesothelioma (L-BAM). This form arises from inherited mutations in the BAP1 gene, distinguishing it biologically from the more common, asbestos-related aggressive mesothelioma.

Unlike traditional forms that tend to resist standard therapies, L-BAM often responds well to treatment, enabling some patients to live near-normal lifespans. However, individuals with this variant are at increased risk for other cancers, including melanoma, kidney, breast, and liver cancers. Therefore, regular screening and early detection are crucial for managing health outcomes.

Dr. Carbone emphasizes that recognizing L-BAM as a separate disease entity allows clinicians to improve diagnostic accuracy and tailor therapies effectively. This discovery provides new hope to families previously facing a uniformly lethal cancer.

The research has significant implications in Hawaiʻi and globally. Mesothelioma is a rare cancer affecting the linings of the lungs and abdomen, with approximately 3,000 new cases annually in the United States, leading to around 2,500 deaths. In Hawaiʻi, about ten cases are diagnosed each year. The identification of the genetic basis of this disease originated from studies of families in Louisiana, Wisconsin, and remote Turkish villages. Genetic analysis of these families, some of whom traveled to Hawaiʻi for screening, helped uncover the mutation.

Subsequent research demonstrated the presence of this variant across diverse populations, including Chinese, Japanese, Native Hawaiian, Jewish, Palestinian, and White families. Today, genetic testing for BAP1 mutations is accessible both in the U.S. and internationally.

This breakthrough underscores the global impact of research conducted at the University of Hawaiʻi Cancer Center, highlighting how local studies can significantly influence international health strategies. The findings encourage ongoing efforts to improve early diagnosis, personalized treatments, and screening protocols to better serve patients worldwide.